BM-32 CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety were evaluated in a subset of patients with BM in the phase I ASCEND-1 study. In 246 patients with ALK+ NSCLC who received ceritinib 750 mg/day, overall response rate (ORR) w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shaw, Alice, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Ross Camidge, D., Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Geraldes, Margarida, Sen, Paramita, Boral, Anthony J., Yovine, Alejandro, Kim, Dong-Wan
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217934/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou240.32
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars